Johanna Mercier Sells 3,000 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) Stock

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) insider Johanna Mercier sold 3,000 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $110.17, for a total transaction of $330,510.00. Following the completion of the sale, the insider now directly owns 120,168 shares of the company's stock, valued at approximately $13,238,908.56. This represents a 2.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Johanna Mercier also recently made the following trade(s):

• On Thursday, May 22nd, Johanna Mercier sold 28,000 shares of Gilead Sciences stock. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00.

Gilead Sciences Price Performance

NASDAQ:GILD traded up $0.50 on Friday, reaching $108.50. 23,266,621 shares of the company's stock traded hands, compared to its average volume of 7,756,139. The firm has a market cap of $134.97 billion, a PE ratio of 22.84, a P/E/G ratio of 0.70 and a beta of 0.29. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16. The stock has a 50-day simple moving average of $106.07 and a 200-day simple moving average of $102.63. Gilead Sciences, Inc. has a 12 month low of $66.01 and a 12 month high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The company had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. Gilead Sciences's revenue for the quarter was down .3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.32) EPS. Equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.91%. The ex-dividend date is Friday, June 13th. Gilead Sciences's payout ratio is 66.53%.

Hedge Funds Weigh In On Gilead Sciences

Several institutional investors have recently bought and sold shares of the business. Smallwood Wealth Investment Management LLC purchased a new position in Gilead Sciences in the first quarter worth about $25,000. Activest Wealth Management increased its position in shares of Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 227 shares during the last quarter. Goodman Advisory Group LLC purchased a new stake in Gilead Sciences during the 1st quarter valued at $29,000. Colonial Trust Advisors lifted its position in Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 213 shares during the last quarter. Finally, Core Alternative Capital boosted its stake in Gilead Sciences by 370.8% during the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 241 shares during the period. Institutional investors own 83.67% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Morgan Stanley upped their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. JPMorgan Chase & Co. increased their price objective on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Wells Fargo & Company boosted their target price on Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price target on the stock. Finally, Oppenheimer dropped their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, April 25th. Nine investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of "Moderate Buy" and an average price target of $110.55.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.